CONfident Treatment Decisions in Living With Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
Pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or low disease activity in RA.

Detailed Description
-----------------
Pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or low disease activity in RA. Upon agreement to participate, the patient participants will provide information on their treating physician. This information will be used to invite physicians to complete the physician-educational intervention and offered CME credits for completing the activity. The investigators will recruit participants from a patient registry (1:1 intervention: control) that meet the eligibility criteria. The recruited patients will complete the educational intervention (if randomized to the intervention arm) and the study outcomes will be collected immediately after the intervention and also after the patients most proximate rheumatologist visit (up to 6-months later).

Official Title
-----------------
CONfident Treatment Decisions in Living With Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Other: Patient Educational Intervention
* Other: Patient Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have a patient-reported diagnosis of RA Most recent RAPID3 > 12 collected in the last 6 months Have not changed RA medication in the last 6 months Taking medications that are commonly used in RA (e.g. methotrexate, sulfasalazine, hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab (Humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (Kevzara) , infliximab (remicade), golimumab (Simponi), rituximab (rituxan), abatacept (Orencia), and certolizumab (Cimzia)) Exclusion Criteria: Does not meet inclusion criteria Age < 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient Variation 1<br>Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys. | Other: Patient Educational Intervention<br>* Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity<br>|
| Experimental: Patient Variation 2<br>Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys. | Other: Patient Control<br>* Patients will receive an attention control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient willingness to adopt T2T and the attainment of the T2T goals. | Name of Scale: Choice predisposition scale The scale measures the willingness to change medication. The scale is a 11-point likert type scale that is scored from not willing at all (minimum) to extremely willing (maximum) with an unsure option (neutral). Higher scores (closer to the maximum) indicate a willingness to change medication and desire to further improve their RA disease activity. | Follow-up Survey #1 (after completion of the intervention) |